Skip to content
2000
Volume 26, Issue 1
  • ISSN: 1871-5249
  • E-ISSN: 1875-6166

Abstract

Background

The search for effective treatments for neurodegenerative diseases, particularly Alzheimer's disease, has been fraught with challenges. Alzheimer's disease accounts for 60-80% of dementia cases globally, affecting approximately about 50 million people. Currently, drug repurposing has emerged as a promising strategy in new drug development, attracting significant attention from regulatory agencies, such as the US FDA.

Aims

This study aimed to investigate the potential therapeutic role of dolutegravir in Alzheimer's disease (AD) treatment using a novel network pharmacology approach. Specifically, it explored the interaction of dolutegravir with key molecular targets involved in AD pathology, predicted its effects on relevant biological pathways, and evaluated its viability as a new therapeutic candidate.

Objective

This study employed a network pharmacology framework to evaluate dolutegravir, an antiretroviral drug, as a potential treatment for Alzheimer's disease, shedding light on its possible therapeutic mechanisms.

Methods

A network pharmacology approach was used to predict the drug targets of dolutegravir. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed to identify interacting pathways. Additionally, protein-protein interaction (PPI) network analysis was conducted to assess key interactions and molecular docking studies were performed to evaluate the binding affinity of dolutegravir to the predicted targets.

Results

PPI network analysis revealed that dolutegravir interacted with several key targets, including BRAF, mTOR, MAPK1, MAPK3, NOS1, BACE1, CAPN1, CASP3, CASP7, CASP8, CHUK, IKBKB, PIK3CA, and PIK3CD. KEGG pathway analysis suggested that dolutegravir could influence amyloid-beta formation, amyloid precursor protein metabolism, and the cellular response to amyloid-beta. Molecular docking results showed the highest binding affinity of dolutegravir for PI3KCD (-8.5 kcal/mol) and MTOR (-8.7 kcal/mol).

Conclusion

The findings indicated that dolutegravir holds significant potential in modulating key pathways involved in Alzheimer's disease pathogenesis. These results provide a strong foundation for further investigations into the therapeutic efficacy and safety of dolutegravir in the treatment of Alzheimer's disease. The use of drug repurposing strategies, leveraging Dolutegravir's established pharmacological profile, offers a promising route for accelerated therapeutic development in AD.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsamc/10.2174/0118715249350698250317041551
2025-04-11
2026-03-06

  • From This Site

    /content/journals/cnsamc/10.2174/0118715249350698250317041551
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. 2021 Alzheimer’s disease facts and figures.Alzheimers Dement.202117332740610.1002/alz.12328 33756057
     [Google Scholar]
  2. PrinceM. WimoA. GuerchetM. AliG.C. WuY.T. World Alzheimer report 2015: The global impact of dementia. Alzheimer’s disease international.2015Available from: https://www.alzint.org/u/WorldAlzheimerReport2015.pdf
  3. HardyJ. SelkoeD.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics.Science2002297558035335610.1126/science.1072994 12130773
     [Google Scholar]
  4. AshburnT.T. ThorK.B. Drug repositioning: Identifying and developing new uses for existing drugs.Nat. Rev. Drug Discov.20043867368310.1038/nrd1468 15286734
     [Google Scholar]
  5. NosengoN. Can you teach old drugs new tricks?Nature2016534760731431610.1038/534314a 27306171
     [Google Scholar]
  6. OpreaT.I. MestresJ. Drug repurposing: Far beyond new targets for old drugs.AAPS J.201214475976310.1208/s12248‑012‑9390‑1 22826034
     [Google Scholar]
  7. Drug Development and Drug Interactions: Table of SubstratesInhibitors and Inducers2020
     [Google Scholar]
  8. NightingaleS. WinstonA. LetendreS. MichaelB.D. McArthurJ.C. KhooS. SolomonT. Controversies in HIV-associated neurocognitive disorders.Lancet Neurol.201413111139115110.1016/S1474‑4422(14)70137‑1 25316020
     [Google Scholar]
  9. YuanZ. WangX. Drug repurposing in the era of precision medicine.Drug Discov. Today202025610271031
     [Google Scholar]
  10. HopkinsA.L. Network pharmacology: The next paradigm in drug discovery.Nat. Chem. Biol.200841168269010.1038/nchembio.118 18936753
     [Google Scholar]
  11. LiS. ZhangB. Traditional Chinese medicine network pharmacology: Theory, methodology and application.Chin. J. Nat. Med.201311211012010.1016/S1875‑5364(13)60037‑0 23787177
     [Google Scholar]
  12. ChengF. DesaiR.J. HandyD.E. WangR. SchneeweissS. BarabásiA.L. LoscalzoJ. Network-based approach to prediction and population-based validation of in silico drug repurposing.Nat. Commun.201891269110.1038/s41467‑018‑05116‑5 30002366
     [Google Scholar]
  13. JourdanJ.P. BureauR. RochaisC. DallemagneP. Drug repositioning: A brief overview.J. Pharm. Pharmacol.20207291145115110.1111/jphp.13273 32301512
     [Google Scholar]
  14. MoreS.A. PatilA.S. SakleN.S. MokaleS.N. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.Virology2021555101810.1016/j.virol.2020.12.006 33421743
     [Google Scholar]
  15. MohiteP. LokwaniD.K. SakleN.S. Exploring the therapeutic potential of SGLT2 inhibitors in cancer treatment: Integrating in silico and in vitro investigations.Naunyn Schmiedebergs Arch. Pharmacol.202439786107611910.1007/s00210‑024‑03021‑x 38416196
     [Google Scholar]
  16. RathiK. WavhaleR. BholeR. UndaleV. ChaudhariS. Rational drug repurposing for alzheimer’s treatment using in-silico ligand and structure-based approaches.Braz. J. Pharm. Sci.202460e2361810.1590/s2175‑97902024e23618
     [Google Scholar]
  17. KardileR.A. SarkateA.P. LokwaniD.K. TiwariS.V. AzadR. ThopateS.R. Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions.Eur. J. Med. Chem.2023245Pt 111488910.1016/j.ejmech.2022.114889 36375337
     [Google Scholar]
  18. ChenL. WangL. GuQ. XuJ. An in silico protocol for identifying mTOR inhibitors from natural products.Mol. Divers.201418484185210.1007/s11030‑014‑9543‑5 25156384
     [Google Scholar]
  19. BartonN. ConveryM. CooperA.W.J. DownK. HamblinJ.N. InglisG. PeaceS. RowedderJ. RowlandP. TaylorJ.A. WellawayN. Discovery of potent, efficient, and selective inhibitors of phosphoinositide 3-kinase δ through a deconstruction and regrowth approach.J. Med. Chem.20186124110611107310.1021/acs.jmedchem.8b01556 30532965
     [Google Scholar]
  20. GrinterS. ZouX. Challenges, applications, and recent advances of protein-ligand docking in structure-based drug design.Molecules2014197101501017610.3390/molecules190710150 25019558
     [Google Scholar]
  21. SakleN.S. MoreS.A. MokaleS.N. A network pharmacology-based approach to explore potential targets of Caesalpinia pulcherima: An updated prototype in drug discovery.Sci. Rep.20201011721710.1038/s41598‑020‑74251‑1 33057155
     [Google Scholar]
  22. BrownD.A. O’RourkeB. Adenosine A2A receptors and their role in Parkinson’s disease.Neurology20107410Suppl. 1S21S25
     [Google Scholar]
  23. ClaudiaR. IsraelC. BenjamínF. FloránL. Dopamine receptors and neurodegeneration.Aging Dis.20156534936810.14336/AD.2015.0330 26425390
     [Google Scholar]
  24. SelkoeD.J. HardyJ. The amyloid hypothesis of Alzheimer’s disease at 25 years.EMBO Mol. Med.20168659560810.15252/emmm.201606210 27025652
     [Google Scholar]
  25. CummingsJ.L. MorstorfT. Treatment for agitation in Alzheimer’s disease: A systematic review and meta-analysis.Neurology2014145395405
     [Google Scholar]
  26. McGeerP.L. McGeerE.G. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: Implications for therapy.Acta Neuropathol.2013126447949710.1007/s00401‑013‑1177‑7 24052108
     [Google Scholar]
  27. De FeliceF.G. FerreiraS.T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease.Diabetes20146372262227210.2337/db13‑1954 24931033
     [Google Scholar]
  28. YangY. MufsonE.J. HerrupK. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease.J. Neurosci.20032372557256310.1523/JNEUROSCI.23‑07‑02557.2003 12684440
     [Google Scholar]
  29. NagA. DhullN. GuptaA. Evaluation of tea (Camellia sinensis L.) phytochemicals as multi-disease modulators, a multidimensional in silico strategy with the combinations of network pharmacology, pharmacophore analysis, statistics and molecular docking.Mol. Divers.202327148750910.1007/s11030‑022‑10437‑1 35536529
     [Google Scholar]
  30. HuangW. JiangY. PI3K/Akt signaling in the pathogenesis of Alzheimer’s disease: Therapeutic perspectives.J. Neurol. Sci.2020415116885
     [Google Scholar]
  31. SinghB. SharmaB. Modulating mTOR signaling in neurodegeneration: Recent insights.Neuropharmacology2022207108939
     [Google Scholar]
  32. XuY. ZhouH. Autophagy and Alzheimer’s disease: MTOR as a critical regulator.Prog. Neurobiol.2023217102631
     [Google Scholar]
/content/journals/cnsamc/10.2174/0118715249350698250317041551
Loading
Exploring the Potential of Dolutegravir in Alzheimer's Disease Treatment: Insights from Network Pharmacology and In Silico Docking Studies
Central Nervous System Agents in Medicinal Chemistry 26, 103 (2026); https://doi.org/10.2174/0118715249350698250317041551
/content/journals/cnsamc/10.2174/0118715249350698250317041551
/content/journals/cnsamc/10.2174/0118715249350698250317041551
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Alzhimers disease; dolutegravir; drug repurposing; KEGG pathway; molecular docking; network pharmacology

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test